Study of REGN6569 and Cemiplimab in Adult Patients with Advanced Solid Tumor Malignancies

2022-500868-36-00 Protocol R6569-ONC-1933 Human pharmacology (Phase I) - First administration to humans Ended

Start 11 Aug 2021 · End 8 Feb 2025 · Status Ended · 1 EU/EEA countries · 6 sites · Protocol R6569-ONC-1933

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 85
Countries 1
Sites 6

Squamous Cell Carcinoma of Head and Neck

Key facts

Sponsor
Regeneron Pharmaceuticals Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
11 Aug 2021 → 8 Feb 2025
Decision date (initial)
2024-09-03
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2022-500868-36-00
EudraCT number
2020-000075-20
ClinicalTrials.gov
NCT04465487

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Squamous Cell Carcinoma of Head and Neck

VersionLevelCodeTermSystem organ class
26.1 PT 10060121 Squamous cell carcinoma of head and neck 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Regeneron Pharmaceuticals Inc.

Sponsor organisation
Regeneron Pharmaceuticals Inc.
Address
777 Old Saw Mill River Road
City
Tarrytown
Postcode
10591-6717
Country
United States

Scientific contact point

Organisation
Regeneron Pharmaceuticals Inc.
Contact name
Clinical Trial Information

Public contact point

Organisation
Regeneron Pharmaceuticals Inc.
Contact name
Clinical Trial Information

Locations

1 EU/EEA country · 6 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 19 6
Rest of world
United States, Georgia, Korea, Republic of
66

Investigational sites

Spain

6 sites · Ended
Hospital Universitario Ramon Y Cajal
Oncology, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
Hospital Universitario Hm Sanchinarro
Oncology, Calle Ona 10, 28050, Madrid
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Institut Catala D'oncologia
Oncology, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
MD Anderson Cancer Center
Oncology, Calle De Arturo Soria Nº 270, 28033, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2021-08-11 2021-08-11 2024-10-09

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-30 Spain Acceptable with conditions
2024-09-03
2024-09-03